Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CSLCSLLY +3.08%67 Capex-to-Operating-Cash-Flow is 0.28 as of Jun. 2026, which is 44% below its 10-year median of 0.50. GuruFocus rates CSLLY with a GF Score™ of 67/100 and a GF Value™ of $47.61 (Significantly Undervalued). The stock has 6 warning signs investors should review. Among 246 Biotechnology companies, CSL ranks worse than 50.41% on this metric.
Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.
Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.
Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.
CSL Capex-to-Operating-Cash-Flow Related Terms
CSL Capex-to-Operating-Cash-Flow Historical Data
* Premium members only.
The historical data trend for CSL's Capex-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSLLY vs VRTX, REGN, MRNA: Capex-to-Operating-Cash-Flow Comparison
For the Biotechnology subindustry, CSL's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CSL Capex-to-Operating-Cash-Flow vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CSL's Capex-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where CSL's Capex-to-Operating-Cash-Flow falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Capex-to-Operating-Cash-Flow of 0.28 mean?
CSL (CSLLY) has a Capex-to-Operating-Cash-Flow of 0.28 as of Jun. 2026. Capex to Operating Cash Flow ratio assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. View historical data on CSL and its competitors. This is 44% below median its historical median of 0.50. Over the past decade, CSL's Capex-to-Operating-Cash-Flow has ranged from 0.29 to 0.78. According to the industry distribution chart, CSL ranks #124 out of 246 companies in the Biotechnology industry, placing it in the top 50.4%.
Is CSL's Capex-to-Operating-Cash-Flow too high?
CSL's current Capex-to-Operating-Cash-Flow of 0.28 is 44% below median its 10-year median of 0.50. Over the past 10 years, this metric has ranged from a low of 0.29 to a high of 0.78. The Biotechnology industry median Capex-to-Operating-Cash-Flow is 0.37. CSL's value of 0.28 is 23.3% below this industry median. Based on the distribution chart, CSL ranks #124 out of 246 companies in the Biotechnology industry, which is below the industry midpoint. Overall, CSL has a GF Score™ of 67/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CSL's Capex-to-Operating-Cash-Flow compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CSL ranks #124 out of 246 companies for Capex-to-Operating-Cash-Flow. This places CSL in the lower half of its industry. The industry median Capex-to-Operating-Cash-Flow is 0.37. CSL's value of 0.28 is 23.3% below this benchmark. Historically, CSL's own Capex-to-Operating-Cash-Flow has ranged from 0.29 to 0.78 over the past decade. While the company's 10-year median is 0.50 vs. the industry median of 0.37, CSL has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Capex-to-Operating-Cash-Flow for a Biotechnology company?
The median Capex-to-Operating-Cash-Flow among Biotechnology companies is 0.37, based on 246 companies in the industry. Companies in the top quartile (top 25%) have a Capex-to-Operating-Cash-Flow significantly above this median, while those in the bottom quartile fall well below. However, Capex-to-Operating-Cash-Flow should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CSL's current Capex-to-Operating-Cash-Flow of 0.28 is 23.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Capex-to-Operating-Cash-Flow mean?
A high Capex-to-Operating-Cash-Flow can signal that a stock is expensive relative to its fundamentals. Capex to Operating Cash Flow ratio assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. View historical data on CSL and its competitors. For the Biotechnology industry, the median Capex-to-Operating-Cash-Flow is 0.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CSL's current Capex-to-Operating-Cash-Flow is 0.28, which is 44% below median its own 10-year median of 0.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CSL stock overvalued right now?
Based on GuruFocus' analysis, CSL (CSLLY) is currently considered Significantly Undervalued. The stock's GF Value™ is $47.61, compared to a current price of $31.67 — trading 33.5% below its estimated fair value. The current Capex-to-Operating-Cash-Flow is 0.28, which is 44% below median its 10-year median of 0.50 and 23.3% below the Biotechnology industry median of 0.37. CSL's overall GF Score™ is 67/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Capex-to-Operating-Cash-Flow calculated?
Capex-to-Operating-Cash-Flow is calculated from a company's financial statements. For CSL (CSLLY), the current Capex-to-Operating-Cash-Flow is 0.28 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CSL (CSLLY) Overvalued in 2026?
Based on GuruFocus' analysis, CSL stock appears to be undervalued.
The current stock price of $31.67 is trading 33.5% below its estimated GF Value™ of $47.61.
GuruFocus considers CSL to be Significantly Undervalued.
Key valuation signals for CSLLY:
Capex-to-Operating-Cash-Flow: 0.28 (44% below median its 10-year median of 0.50)
GF Value™: $47.61 vs. price of $31.67 (33.5% below fair value)
Industry Position: 23.3% below the Biotechnology median (#124 of 246)
No single metric tells the full story. See the CSLLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CSL is one of the largest global biotech companies and has three main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world's second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.
67GF Score
Get the complete analysis for CSLLY
Capex-to-Operating-Cash-Flow is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSLLY has been successfully added to your 
